Despite potential short-cuts, drug development is a lengthy and risky process that culminates in marketing approval. However, just because a drug achieves regulatory approval, does not mean that it will be instantly available to those in need. […]
What is federated learning? Federated learning (FL) is a machine learning paradigm that allows to train algorithms collaboratively without the need for source data exchange between the parties. This means that different institutions or companies can join […]
Check out my latest monthly review! It summarises Blue Steens’ latest posts and showcases some informative online content that I haven’t released elsewhere. Click to read >>>
I feel that there is considerable confusion about drug prices amongst industry outsiders. Until I started looking into the topic, I had no idea how complex it was.
In 2019, I graduated with Distinction from the roller-coaster that was my one-year full-time MSc in Finance and Investment Management at the University of Aberdeen, Scotland.
Thoughts on: Why you shouldn’t fear the gray tsunami, David Rotman, 21 Aug 2019 The above article kept cropping up in my Twitter feed a few times until I finally gave in and read it. It discusses […]